Lenvima, also known as Lenvatinib 10 Mg Capsules, is an oral medication used to treat certain types of cancer, including thyroid, kidney, and liver cancer. It is a highly effective kinase inhibitor that blocks the activity of specific proteins that promote the growth and survival of cancer cells. Lenvima is available in the form of capsules containing 10 mg of Lenvatinib as the active ingredient.
Lenvima is manufactured by Eisai Co., Ltd., a Japanese multinational pharmaceutical company that is committed to developing safe, effective, and innovative medical solutions for various medical conditions. The company has a strong research and development team that works tirelessly to create new pharmaceuticals to address unmet medical needs.
The active ingredient of Lenvima, Lenvatinib, works by preventing the growth and division of cancer cells by blocking the activity of specific proteins involved in cell division and proliferation. This leads to a reduction in the size and number of cancer cells and can help patients achieve better treatment outcomes.
Lenvima is prescribed by a qualified healthcare provider and is usually taken once a day orally, with or without food. The dosage of Lenvima depends on the patient’s medical history, age, and other medical conditions, and is determined by the healthcare provider. The duration of treatment may vary and will depend on the type of cancer being treated, the patient’s overall health, and response to the medication.
Despite its effectiveness in treating certain types of cancer, Lenvima may cause some side effects such as fatigue, loss of appetite, hypertension, diarrhea, weight loss, proteinuria, and gastrointestinal perforation in some cases. Patients should discuss the possible side effects of Lenvima with their healthcare provider before commencing treatment.
In conclusion, Lenvima (Lenvatinib 10 Mg Capsules) is an oral medication used to treat kidney, liver, and thyroid cancer. The drug is manufactured by Eisai Co., Ltd, a reputable pharmaceutical company that is renowned for its dedication to providing innovative medicines worldwide. The active ingredient in Lenvima, Lenvatinib, blocks the activity of proteins that promote cancer cell growth and division. Patients should be monitored closely by their healthcare providers during treatment and should discuss possible side effects before starting treatment. With proper medication management, Lenvima can help patients achieve better treatment outcomes, leading to improved quality of life.